News
MedInvest is hosting a Biotech and Pharma Investor Conference March 31-April 1, 2026 in New York City. NIH’s Steve Ferguson and Michael Salgaller will be speaking. They will be discussing NIH as a premier technology transfer partner, how the process at the NIH works, and answering questions! This is
Currently, there is no effective treatment for many types of retinal degeneration. Nor are there sufficient treatments for autoimmune uveitis, as current uveitis treatment primarily uses steroidal anti-inflammatory medication, which can produce significant unwanted side effects with long-term use
NIH inventors have developed an image-based machine learning system that is able to validate functional cell phenotypes. The system may be trained to automatically recognize image features that correlate with a desired cell-type or properties for research, diagnostic, and therapeutic purposes. This
NIH inventors have developed a mutation-independent method to treat Leber congenital amaurosis (LCA), retinitis pigmentosa (RP), other inherited retinal degenerations (IRDs), and age-related macular degeneration (AMD) using the FDA-approved small molecule, Halofantrine. NIH inventors found